MDT-AP-0714
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 12
- os_event
- true
- age_years
- 5.91
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.265314601
- umap2_2d
- 1.507765434
- umap1_3d
- 0.488597144
- umap2_3d
- -2.465732085
- umap3_3d
- -1.14179122
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.490
- DNA_REPAIR+0.440
- MYC_TARGETS_V2+0.370
- MYC_TARGETS_V1+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.330
- WNT_BETA_CATENIN_SIGNALING+0.290
- MITOTIC_SPINDLE+0.270
- ADIPOGENESIS+0.150
- OXIDATIVE_PHOSPHORYLATION+0.120
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- APICAL_SURFACE-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- MYOGENESIS-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- ANGIOGENESIS-0.340
- TNFA_SIGNALING_VIA_NFKB-0.320
- KRAS_SIGNALING_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TV5B86ZD | Embryonal tumors | — | 0.928 |
| 2 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.922 |
| 3 | ERR2598206 | fetal | fetal | 0.921 |
| 4 | SRR13780247 | — | cohortMD1 | 0.920 |
| 5 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.916 |
| 6 | BS_5P1TN10Z | Embryonal tumors | — | 0.916 |
| 7 | SRR12475147 | — | — | 0.915 |
| 8 | MDT-AP-0156 | Med | Medulloblastoma | 0.913 |
| 9 | BS_VJ2S5DVS | Ependymoma NOS | — | 0.911 |
| 10 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |